{"id":179325,"date":"2026-02-03T06:51:56","date_gmt":"2026-02-03T11:51:56","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179325"},"modified":"2026-02-03T06:51:58","modified_gmt":"2026-02-03T11:51:58","slug":"corona-q3-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/corona-q3-fy26-earnings-results\/","title":{"rendered":"Corona Q3 FY26 Earnings Results"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Executive Summar<\/strong>y<\/h2>\n\n\n\n<p>Corona Remedies Ltd reported Q3FY26 revenues of \u20b9342 crore, up 14.37% YoY, with consolidated net profit increasing 39.13% to \u20b964 crore despite higher expenses. Strong pharmaceutical demand drove topline growth while operational efficiencies supported margin expansion amid industry tailwinds.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Revenue &amp; Growth<\/strong><\/h2>\n\n\n\n<p>Revenues grew to \u20b9342 crore from \u20b9298 crore YoY, reflecting solid 15% expansion primarily from branded generics and chronic therapy portfolios. Total expenses rose 11.18% YoY to \u20b9507 crore, moderated relative to revenue acceleration through better supply chain management.<\/p>\n\n\n\n<p><strong>Profitability &amp; Margins<\/strong><br>Consolidated net profit surged 39.13% YoY to \u20b964 crore from \u20b945 crore, with EBITDA reaching \u20b983 crore at impressive 24.3% margins (up 100 bps YoY). Basic EPS improved 36.84% to \u20b92.08 from \u20b91.52, excluding one-time labor code provisions.<\/p>\n\n\n\n<p><strong>Balance-Sheet Highlights<\/strong><br>The dataset shows healthy liquidity with net working capital days at 18 and strong OCF\/EBITDA conversion of 86.3% for 9MFY26. Annualized RoE at 31.1% and RoCE at 48% highlight capital efficiency in pharma operations.<\/p>\n\n\n\n<p><strong>Cash Flow \/ Liquidity<\/strong><br>9M FY26 operating cash flow demonstrates high-quality earnings with 86.3% EBITDA conversion, supporting working capital needs and growth capex.<\/p>\n\n\n\n<p><strong>Key Ratios \/ Metrics<\/strong><br>EBITDA margin expanded to 24.3%; PAT margin at 16.2% (adjusted). 9M revenue up 16.3% to \u20b91,050 crore with PAT growth of 30.7% to \u20b9154 crore, positioning for sustained pharma sector momentum.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR-839x1024.png\" alt=\"\" class=\"wp-image-179326\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Executive Summary Corona Remedies Ltd reported Q3FY26 revenues of \u20b9342 crore, up 14.37% YoY, with consolidated net profit increasing 39.13% to \u20b964 crore despite higher expenses. Strong pharmaceutical demand drove topline growth while operational efficiencies supported margin expansion amid industry tailwinds. Revenue &amp; Growth Revenues grew to \u20b9342 crore from \u20b9298 crore YoY, reflecting solid [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":179326,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-179325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/COR.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":179328,"url":"https:\/\/alphastreet.com\/india\/campus-q3-fy26-earnings-results\/","url_meta":{"origin":179325,"position":0},"title":"Campus Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"February 3, 2026","format":false,"excerpt":"Executive Summary Campus Activewear Ltd reported Q3FY26 revenues of \u20b9589 crore, up 14.37% YoY, with consolidated net profit increasing 39.13% to \u20b964 crore. Expense growth moderated to 11.18% YoY, delivering strong operating leverage in sports and athleisure footwear amid rising domestic fitness demand. Revenue & Growth Revenues expanded to \u20b9589\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/CAM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178326,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":179325,"position":1},"title":"Gland Pharma Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of \u20b91,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to \u20b9261 crore. Total expenses increased 20.03% YoY to \u20b91,372 crore, reflecting strong revenue growth with controlled cost escalation. Revenue & Growth Revenues grew to \u20b91,695.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178128,"url":"https:\/\/alphastreet.com\/india\/innova-captab-q3-fy26-earnings-results\/","url_meta":{"origin":179325,"position":2},"title":"Innova Captab Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 28, 2026","format":false,"excerpt":"Executive Summary Innova Captab Ltd reported Q3FY26 revenues of \u20b9450 crore, up 42.41% YoY, with consolidated net profit rising 23.53% to \u20b942 crore. Total expenses increased 44.0% YoY to \u20b9396 crore, reflecting strong revenue momentum despite cost pressures. Revenue & Growth Revenues jumped to \u20b9450.00 crore in Q3FY26 from \u20b9316.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177861,"url":"https:\/\/alphastreet.com\/india\/granules-india-q3-fy26-earnings-results\/","url_meta":{"origin":179325,"position":3},"title":"Granules India Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 27, 2026","format":false,"excerpt":"Executive Summary Granules India Ltd reported Q3FY26 revenues of \u20b91,388 crore, up 21.97% YoY, with consolidated net profit rising 27.12% to \u20b9150 crore. Total expenses increased 19.37% YoY to \u20b91,183 crore, reflecting efficient cost management amid strong revenue growth. Revenue & Growth Revenues grew to \u20b91,388.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":179325,"position":4},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178356,"url":"https:\/\/alphastreet.com\/india\/eclerx-services-q3-fy26-earnings-results\/","url_meta":{"origin":179325,"position":5},"title":"eClerx Services Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary eClerx Services Ltd reported Q3FY26 revenues of \u20b91,070 crore, up 25.29% YoY, with consolidated net profit rising 40.15% to \u20b9192 crore. Total expenses increased 23.19% YoY to \u20b9850 crore, demonstrating strong operating leverage in business process management services. Revenue & Growth Revenues grew to \u20b91,070.00 crore in Q3FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/E-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179325"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179325\/revisions"}],"predecessor-version":[{"id":179327,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179325\/revisions\/179327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/179326"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}